Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 238 of the 265 references it cites were found in a registry or an index; 17 of the 323 sources its claims cite were checked for support.
Abstract
Objective: Our objective was to formulate a clinical practice guideline for the management of the pregnant woman with diabetes. Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, 5 additional experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and innumerable e-mail communications enabled consensus for all recommendations save one with a majority decision being employed for this single exception. Conclusions: Using an evidence-based approach, this Diabetes and Pregnancy Clinical Practice Guideline addresses important clinical issues in the contemporary management of women with type 1 or type 2 diabetes preconceptionally, during pregnancy, and in the postpartum setting and in the diagnosis and management of women with gestational diabetes during and after pregnancy.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline provides evidence-based recommendations for managing type 1 or type 2 diabetes preconceptionally, during pregnancy, and postpartum, and for diagnosing and managing gestational diabetes. It uses GRADE and recommends universal early diabetes testing, 24–28 week 75-g OGTT with IADPSG criteria, tight glycemic targets, and lifestyle-first therapy with insulin or selected oral agents when needed.
Key findings
- Universal testing for overt diabetes is recommended at the first prenatal visit before 13 weeks (or as soon as possible thereafter) using fasting plasma glucose, HbA1c, or untimed random plasma glucose; overt diabetes thresholds are fasting ≥126 mg/dL (≥7.0 mmol/L), random ≥200 mg/dL (≥11.1 mmol/L), or HbA1c ≥6.5%, while early gestational diabetes is fasting 92–125 mg/dL (5.1–6.9 mmol/L).
- Gestational diabetes should be tested at 24–28 weeks with a 2-hour 75-g OGTT and diagnosed using IADPSG criteria: fasting 92–125 mg/dL (5.1–6.9 mmol/L), 1-hour ≥180 mg/dL (≥10.0 mmol/L), or 2-hour 153–199 mg/dL (8.5–11.0 mmol/L).
- Glycemic targets are preprandial ≤95 mg/dL (5.3 mmol/L), or ≤90 mg/dL (5.0 mmol/L) if safely achievable; 1-hour postmeal ≤140 mg/dL (7.8 mmol/L); 2-hour postmeal ≤120 mg/dL (6.7 mmol/L); and for overt diabetes HbA1c ≤7% (ideally ≤6.5%).
- Initial gestational diabetes treatment is medical nutrition therapy plus ≥30 minutes daily moderate exercise; pharmacotherapy is recommended if lifestyle is insufficient, with insulin preferred for diagnosis before 25 weeks or fasting plasma glucose >110 mg/dL (6.1 mmol/L), glyburide as a suitable alternative in other cases, and metformin restricted to women who refuse or cannot use insulin or glyburide and are not in the first trimester.
Methods
- The Endocrine Society appointed a Task Force composed of a chair, 5 additional experts, a methodologist, and a medical writer; it used the GRADE system to grade strength of recommendations and quality of evidence.
- The Task Force commissioned two systematic reviews and developed recommendations through one group meeting, several conference calls, and email communications; consensus was achieved for all recommendations except one, which used a majority decision.
- The commissioned reviews included a screening review of 39 original studies enrolling 87,830 women and a glucose-targets review of 34 original studies enrolling 9,433 women (15 randomized controlled trials, 18 cohort studies, and 1 case-control study).
Limitations
- Stated in the text: the quality of evidence for screening remains low because no randomized trials compared screening vs no screening and measured patient-important outcomes; the glucose-targets analysis could not control for maternal BMI and had significant heterogeneity, with sparse data for type 1 and type 2 diabetes and postprandial targets.
- Stated in the text: the recommendation to adopt IADPSG criteria was a majority opinion, not unanimous, and is acknowledged as arguable and controversial; implementation will substantially increase gestational diabetes diagnoses, medicalization of pregnancies, and healthcare costs.
- Evident from the text: many recommendations are ungraded or based on indirect evidence, unsystematic observations, or consensus; some key management recommendations rely on observational studies, and long-term safety data for metformin use in pregnancy are not yet available.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 138 Not checked · 19 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Women with diabetes who receive preconception counseling have better preconception glycemic control (8, 9)”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Preconception care of women with diabetes
What the sources say
- Not checked yetcites [8] Anwar A, Salih A, Masson E, Allen B, Wilkinson L, Lindow SW. The effect of pre-pregnancy counselling for women with pre-gestational diabetes on maternal health status. Eur J Obstet Gynecol Reprod Biol. 2011; 155: 137– 139. 21277071 source
- Partly supportedcites [9] Murphy HR, Roland JM, Skinner TC, et al. Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: Benefits beyond glycemic control. Diabetes Care. 2010; 33: 2514– 2520. 21115765 PMC2992180 sourceExperimental — accuracy not yet measured
The Results (Pregnancy preparation; page unavailable) report that women attending prepregnancy care were more likely to have received counseling and had significantly better glycemic control before pregnancy. The Methods (Maternal data; page unavailable) distinguish counseling from prepregnancy care, however, and the reported glycemic comparison is by care attendance, not counseling alone. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Maternal hyperglycemia in the first few weeks of pregnancy increases the risk of fetal malformations, spontaneous abortions, and perinatal mortality (14–18).”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.2. Evidence
What the sources say
- Supportedcites [14] Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes: systematic review of observational studies. BMC Pregnancy Childbirth. 2006; 6: 30. 17074087 PMC1635059 source
The Background links inadequate glycaemic control around conception to increased congenital-abnormality risk, noting that organogenesis occurs early in pregnancy. The Discussion reports a greater than three-fold risk of congenital malformations with poor versus optimal glycaemic control. The paper describes this as an association, not proof of an exclusive causal effect. (LLM, conf=0.88)
- Not checked yetcites [15] Nielsen GL, Møller M, Sørensen HT. HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care. 2006; 29: 2612– 2616. 17130193 source
- Supportedcites [16] Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007; 30: 1920– 1925. 17446531 source
The introduction states that poor glycemic control in the periconception period is positively associated with congenital anomalies in offspring of women with prepregnancy diabetes. The Implications section adds that elevated periconceptional GHb heightens the risk of structural anomalies, supporting the claim in that population. (LLM, conf=0.91)
- Partly supportedcites [17] Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes. Diabetologia. 2000; 43: 79– 82. 10663219 sourceExperimental — accuracy not yet measured
The Abstract (p. 1) and Discussion (p. 3) report increased fetal-malformation risk with raised HbA1c in early pregnancy. The study concerns women with Type I diabetes and measures HbA1c before 14 weeks; it does not establish the risk specifically for the first few weeks or for pregnant women generally. (LLM, conf=0.84)
- Not checked yetcites [18] Bell R, Glinianaia SV, Tennant PW, Bilous RW, Rankin J. Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. [published online ahead of print April 1, 2012]. Diabetologia. doi: 10.1007/s00125-012-2455-y. 22314812
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Rapid-acting insulin analogs are likely more able than regular human insulin to help a woman achieve postprandial blood glucose targets and are less likely to cause hypoglycemia; fetal outcomes, however, seem comparable (28–30).”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > Insulin therapy
What the sources say
- Not checked yetcites [28] Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, Hansen AS, Mersebach H; Insulin Aspart Pregnancy Study Group. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin. Obstet Gynecol. 2008; 198: 186.e1– e7. 17905178
- Supportedcites [29] Mathiesen ER, Kinsley B, Amiel SA, et al; Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007; 30: 771– 776. 17392539 source
The Pregnancy outcome section (p. 5 of our copy) reports no significant between-treatment difference in live births (IAsp 87.3% vs HI 79.4%), fetal losses (8.9% vs 12.1%) or congenital malformations (4.3% vs 6.6%). The Discussion (Quality-of-life/overall text) states 'Safety profiles of IAsp and HI were comparable... pregnancy outcome was comparable between treatments,' and the Abstract concludes maternal safety profiles and pregnancy outcomes were similar between treatments. This directly supports the paraphrase that fetal outcomes with this rapid-acting analog appear comparable to regular human insulin. (LLM, conf=0.90)
- Not checked yetcites [30] Lapolla A, Dalfrà MG, Spezia R, et al. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol. 2008; 45: 61– 66. 18227964 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Rapid-acting insulin analogs are likely more able than regular human insulin to help a woman achieve postprandial blood glucose targets and are less likely to cause hypoglycemia; fetal outcomes, however, seem comparable (28–30).”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > Insulin therapy
What the sources say
- Not checked yetcites [28] Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, Hansen AS, Mersebach H; Insulin Aspart Pregnancy Study Group. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin. Obstet Gynecol. 2008; 198: 186.e1– e7. 17905178
- Partly supportedcites [29] Mathiesen ER, Kinsley B, Amiel SA, et al; Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007; 30: 771– 776. 17392539 sourceExperimental — accuracy not yet measured
The Hypoglycemic episodes section reports lower observed rates of major hypoglycemia with insulin aspart than with regular human insulin, but the estimated difference was not statistically significant. It also reports similar risks of all and minor hypoglycemia between treatments. Thus the study does not establish that rapid-acting insulin analogs generally are less likely to cause hypoglycemia. (LLM, conf=0.88)
- Not checked yetcites [30] Lapolla A, Dalfrà MG, Spezia R, et al. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol. 2008; 45: 61– 66. 18227964 source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Untreated or insufficiently treated hypothyroidism reduces fertility and, in the event of pregnancy, increases the risk of miscarriage and impaired fetal brain development (64–68).”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > Insulin therapy
What the sources say
- Not checked yetcites [64] Casey BM, Dashe JS, Wells CE, et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005; 105: 239– 245. 15684146 source
- Not checked yetcites [65] Glinoer D, Soto MF, Bourdoux P, et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab. 1991; 73: 421– 427. 1906897 source
- Partly supportedcites [66] Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999; 341: 549– 555. 10451459 sourceExperimental — accuracy not yet measured
Haddow et al. (1999) supports the untreated half of the claim: the Results (p. ~551) report that among the 62 women with thyroid deficiency, the 48 who were not treated during pregnancy had children whose full-scale WISC-III IQ averaged 7 points lower than the 124 matched controls (P=0.005), and the Discussion states that hypothyroidism in pregnant women 'can adversely affect their children's subsequent performance on neuropsychological tests,' even when mild/asymptomatic. However, the 'insufficiently treated' component is not supported and is arguably contrary to our copy: the Results state that 'the test scores of the children whose mothers were being treated (albeit inadequately) during pregnancy were similar to those of the control children in most categories,' and the Discussion concludes that treating maternal hypothyroidism 'appears to be beneficial for the child, even when treatment is inadequate as determined by measurements of thyrotropin.' The paper also frames its conclusion with hedging ('may adversely affect') and measures neuropsychological outcome in the children at 7-9 years rather than fetal brain development directly, so the citing sentence states at face value more than this source establishes. (LLM, conf=0.78)
- Not checked yetcites [67] Leung AS, Millar LK, Koonings PP, Montoro M, Mestman JH. Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol. 1993; 81: 349– 353. 8437784 source
- Not checked yetcites [68] Man EB, Brown JF, Serunian SA. Maternal hypothyroxinemia: psychoneurological deficits of progeny. Ann Clin Lab Sci. 1991; 21: 227– 239. 1859163
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
129 more claims · 4 with their cited sources checked
Create a free account to see all 168 claims and to verify the 302 references still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current guidelines emphasise that MNT should be delivered by a registered dietitian or a healthcare professional with specialised expertise in GDM [8].”
From Medical Nutrition Therapy for Women with Gestational Diabetes: Current Practice and Future Perspectives (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Endocrine Society recommends moderate energy restriction (1600 to 1800 kcal per day) or a 33% reduction in total calories for overweight/obese women with GDM to improve maternal glycaemia without compromising foetal growth or inducing ketosis [8].”
From Medical Nutrition Therapy for Women with Gestational Diabetes: Current Practice and Future Perspectives (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Citations
Cites
1 retracted
Items 201–238 of 238
Short, K. R., Pratt, L. V., & Teague, A. M. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/278678 · Cited by 37
Is insulin lispro safe in pregnant women: does it cause any adverse outcomes on infants or mothers?
Aydın, Y., Berker, D., Direktör, N., Ustün, İ., Tütüncü, Y. A., Işık, S., Delibaşı, T., & Guler, S. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.02.004 · Cited by 36
Metformin before and during pregnancy and lactation in polycystic ovary syndrome
Glueck, C. J., & Wang, P. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.2.191 · Cited by 36 · cited 1×
“08% of the weight-normalized maternal dose, well below the level of concern for breastfeeding (214).”
Grossesse et diabète de type 1 : pompe à insuline versus traitement intensifié conventionnel
Hiéronimus, S., Cupelli, C., Bongain, A., Durand-Réville, M., Berthier, F., & Fénichel, P. (2005) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2005.04.020 · Cited by 36
Holt, R. I. G., Goddard, J. R., Clarke, P., & Coleman, M. A. G. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00974.x · Cited by 36
Perinatal outcomes in pregnancies managed with antenatal insulin glargine
Egerman, R., Ramsey, R., Kao, L., Bringman, J., Haerian, H., Kao, J., & Bush, A. (2009) · American Journal of Perinatology · doi:10.1055/s-0029-1220782 · Cited by 35
Feldberg, D., Dicker, D., Samuel, N., Peleg, D., Karp, M., Goldman, J. A., & Goldman, J. A. (1988) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016348809004231 · Cited by 33
Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome
Gagnon, C., & Baillargeon, J.-P. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060607 · Cited by 33
Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature
Velázquez-Armenta, E. Y., Han, J. Y., Choi, J. S., Yang, K. M., & Nava-Ocampo, A. A. (2007) · Hypertension in Pregnancy · doi:10.1080/10641950601147937 · Cited by 33 · cited 1×
“Evidence ACE inhibitors (51, 52) and angiotensin-receptor blockers (52, 53) are teratogenic (54).”
(1999) · PubMed · Cited by 33
Consequences of intrauterine contraception in diabetic women
Skouby, S. O., Mølsted-Pedersen, L., & Kosonen, A. (1984) · Fertility and Sterility · doi:10.1016/s0015-0282(16)48140-9 · Cited by 32 · cited 1×
“Compared with women without diabetes, women with diabetes using an intrauterine device (copper or levonorgestrel-releasing) are not at increased risk of untoward effects (226–230).”
(2003) · PubMed · Cited by 31
(1980) · PubMed · Cited by 31
Persson, B., & Hansson, U. (1993) · Baillière's Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80216-2 · Cited by 30
Insulin lispro, pregnancy, and retinopathy.
Bhattacharyya, A., & Vice, P. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.12.2101 · Cited by 28
Short, K. R., Pratt, L. V., Teague, A. M., Man, C. D., & Cobelli, C. (2013) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2012.00900.x · Cited by 28 · cited 1×
“Both aerobic exercise (83–86) and non–weight-bearing exercise (87) have been shown to lower blood glucose levels in women with gestational diabetes.”
Preconception care of women with diabetes: The unrevealed obstacles
Holing, E. V. (2000) · The Journal of Maternal-Fetal Medicine · doi:10.1002/(sici)1520-6661(200001/02)9:1<10::aid-mfm4>3.0.co;2-z · Cited by 28
(1994) · PubMed · Cited by 27
Glyburide in gestational diabetes—prediction of treatment failure
Yogev, Y., Melamed, N., Chen, R., Nassie, D., Pardo, J., & Hod, M. (2011) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2010.531323 · Cited by 25
Self-citationRobertson, H., Pearson, D. W. M., & Gold, A. E. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02769.x · Cited by 25 · cited 1×
“Pregnant women with type 1 diabetes are at increased risk of hypoglycemia including severe hypoglycemia, especially during the first trimester (21–25).”
Pitkin, R. (2003) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)03064-8 · Cited by 25
Screening for Gestational Diabetes: A Systematic Review and Meta-Analysis
Prutsky, G. J., Domecq, J. P., Sundaresh, V., Elraiyah, T., Nabhan, M., Prokop, L. J., Vella, A., Montori, V. M., & Murad, M. H. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2460 · Cited by 24
Self-citationUse of insulin glargine throughout pregnancy in 102 women with type 1 diabetes
Lepercq, J., Jacqueminet, S., Hieronimus, S., Timsit, J., & Grimaldi, A. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.11.008 · Cited by 24 · cited 9×
“When appropriate, insulin glargine may be replaced by insulin detemir or NPH insulin.”
InfluentialPregnancy in women with diabetes and ischaemic heart disease
Bagg, W., Henley, P. G., Macpherson, P., & Cundy, T. F. (1999) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.1999.tb03454.x · Cited by 22
Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy
Smith, J., Manuck, T., White, J., & Merrill, D. (2009) · American Journal of Perinatology · doi:10.1055/s-0028-1095181 · Cited by 22
New concepts and applications in the use of the insulin pump during pregnancy
Gabbe, S. G. (2000) · The Journal of Maternal-Fetal Medicine · doi:10.1002/(sici)1520-6661(200001/02)9:1<42::aid-mfm9>3.0.co;2-b · Cited by 21 · cited 2×
“with no greater risk or possibly lower risk (170) of ma-”
(2002) · PubMed · Cited by 19
Studies of Postnatal Diabetes Mellitus in Women Who Had Gestational Diabetes
Wein, P., Beischer, N. A., & Sheedy, M. T. (1997) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.1997.tb02450.x · Cited by 19
The clinical significance of IGF-I in maternal serum during pregnancy in type 1 diabetes
Lauszus, F. F. (2007) · Current Diabetes Reviews · doi:10.2174/157339907781368922 · Cited by 19
Use of hypoglycemic drugs during lactation.
(2009) · Europe PMC (PubMed Central) · Cited by 19
(2012) · PubMed · Cited by 19
Pratoomsoot, C., Smith, H. T., Kalsekar, A., Boye, K. S., Arellano, J., & Valentine, W. J. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02775.x · Cited by 18 · cited 1×
“quality of life (156) and may also provide better postpran-”
The effect of prior exercise on oral glucose tolerance in late gestational women
Young, J. C., & Treadway, J. L. (1992) · European Journal of Applied Physiology and Occupational Physiology · doi:10.1007/bf00625062 · Cited by 16
(1980) · PubMed · Cited by 15
Kimmerle, R., Heinemann, L., & Berger, M. (1995) · Diabetes Care · doi:10.2337/diacare.18.11.1506b · Cited by 10
Anwar, A., Salih, A., Masson, E., Allen, B., Wilkinson, L., & Lindow, S. W. (2011) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.12.017 · Cited by 8 · cited 1×
“Evidence Women with diabetes who receive preconception counseling have better preconception glycemic control (8, 9) and are more likely to have favorable pregnancy outcomes, including lower rates of congenital anomalies (9, 10) and spontaneous abortions (11, 12).”
Lövestam-Adrian (1997) · Research Portal (Queen's University Belfast) · doi:10.1002/(sici)1096-9136(199712)14:12 · Cited by 4
Leguizamon (2000) · doi:10.1002/(sici)1520-6661(200001/02)9:1<70::aid-mfm15>3.0.co;2-#
Research works printed but not linked: 8
- Langer, 2000, Level of glycemia and perinatal outcome in pregestational diabetes, J Matern Fetal Med, 9, 35, 10.1002/(SICI)1520-6661(200001/02)9:1<35::AID-MFM8>3.0.CO;2-6 · doi:10.1002/(sici)1520-6661(200001/02)9:1
- Confidential Enquiry into Maternal and Child Health (CEMACH), 2007, Diabetes in Pregnancy: Are We Providing the Best Care? Findings of a National Enquiry: England, Wales and Northern Ireland
- Leguizamon, 2000, Effect of medical therapy on progressive nephropathy: influence of pregnancy, diabetes and hypertension, J Matern Fetal Med, 9, 70, 10.1002/(SICI)1520-6661(200001/02)9:1<70::AID-MFM15>3.0.CO;2-# · doi:10.1002/(sici)1520-6661(200001/02)9:1
- Voelmle, 2007, Fetal outcomes and improved A1c values in pregnant women with type 1 diabetes using real-time continuous glucose sensors, Diabetes, 56, A117
- American Dietetic Association, 2002, Nutrition Practice Guidelines for Gestational Diabetes [CD-ROM]
- American Diabetes Association, 2000, American Diabetes Association: gestational diabetes (position statement), Diabetes Care, 23, S77
- Mimouni, 1987, Perinatal asphyxia in infants of diabetic mothers is associated with maternal vasculopathy and hyperglycaemia in labour, Neonat Epidemiol Follow-up, 400A
- Mayer-Davis, 2006, Breast-feeding and risk for childhood obesity: does maternal diabetes or obesity status matter?, Diabetes Care, 29, 2231, 10.2337/dc06-0974 · DOI · Paper page
Cited by
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
Epidemiology and management of gestational diabetes
Sweeting, A., Hannah, W., Backman, H., Catalano, P., Feghali, M., Herman, W. H., Hivert, M.-F., Immanuel, J., Meek, C., Oppermann, M. L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00825-0 · Cited by 431
Duran, A., Sáenz, S., Torrejón, M. J., Bordiú, E., del Valle, L., Galindo, M., Perez, N., Herraiz, M. A., Izquierdo, N., Rubio, M. A., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0179 · Cited by 335
“8 mmol/L]), together with obstetric and pediatric monitoring as previously reported (14,15) and recommended by the Endocrine Society (7).”
BackgroundInfluentialBehboudi-Gandevani, S., Amiri, M., Bidhendi Yarandi, R., & Ramezani Tehrani, F. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0406-1 · Cited by 321
Metadata
- Authors
- Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y.
- Affiliations
- Charles H. Best Diabetes Centre (I.B.), Whitby, Ontario, Canada L1M 1Z5
- Helen Schneider Hospital for Women (E.H., Y.Y.), Petach Tikva 49100, Israel
- Royal Victoria Hospital (GB)
- Sansum Diabetes Research Institute (US)
- University of Southern California (US)
- Mayo Clinic (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-11-01
- Volume
- 98
- Issue
- 11
- Pages
- 4227-4249
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC8998095
- OpenAlex
- W2109023860
- Semantic Scholar
- 2f63722c3f2b6b74d13e1f6171075ebf1a4f8cce
- Cited by
- 561
- References
- 265
- Citations by year
- 2026: 9 · 2025: 30 · 2024: 40 · 2023: 42 · 2022: 61 · 2021: 46 · 2020: 47 · 2019: 62 · 2018: 55 · 2017: 43 · 2016: 46 · 2015: 47 · 2014: 28 · 2013: 2
- FWCI
- 45.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes in pregnancy, gestational diabetes mellitus, type 1 diabetes, type 2 diabetes, preconception care, postpartum care, glycemic control, diabetes management in pregnancy
- MeSH terms
- Endocrinology, Female, Humans, Pregnancy, Pregnancy in Diabetics, Societies, Medical, Practice Guidelines as Topic, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.